Milestone Pharmaceuticals Inc. said China’s NMPA approval of etripamil nasal spray for PSVT marks the first regulatory approval of etripamil outside the United States.
The approval triggers a $2 million milestone payment to Milestone Pharmaceuticals.
Everest Medicines holds the exclusive license for etripamil nasal spray in Greater China.
Under the agreement with Everest, Milestone is eligible for up to $98 million in milestones and up to 18% royalties in Greater China.
MIST•
